Diabetic autonomic neuropathy

Summary

Diabetic autonomic neuropathy (MONDO:0001299) is a disease and 8 clinical trials. Top therapeutic interventions include bromocriptine mesylate and quinapril. A subtype of autonomic neuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	diabetic autonomic neuropathy
Mondo ID	MONDO:0001299
DOID	DOID:11503
ICD-11	1129679469
NCIT	C27068
SNOMED CT	50620007
UMLS	C0271686
MedGen	82887
Is cancer (heuristic)	no

Disease family

This is a subtype of autonomic neuropathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autonomic nervous system disorder › autonomic neuropathy › diabetic autonomic neuropathy

Related subtypes (1): Horner syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE4	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00752440	PHASE4	UNKNOWN	Inspiratory Muscle Training in Patients With Autonomic Neuropathic
NCT02682901	PHASE4	COMPLETED	Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects
NCT03031834	PHASE4	COMPLETED	Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus
NCT00116207	PHASE3	COMPLETED	An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes
NCT06432270	Not specified	NOT_YET_RECRUITING	Effect of Diabetes Mellitus on Cardiac Autonomic Function in Surgical Patients Undergoing General Anesthesia
NCT00919347	Not specified	COMPLETED	The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction
NCT02573519	Not specified	TERMINATED	Gastrointestinal Motility Among Diabetes Patients
NCT06734143	Not specified	COMPLETED	High Diagnostic Performance of the Indicator Plaster Neuropad for the Detection of Diabetic Autonomic Neuropathy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BROMOCRIPTINE MESYLATE	4	1
QUINAPRIL	4	1